- Home
- NRIX vs TBLD Comparison
NRIX vs TBLD Comparison
Compare NRIX & TBLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- TBLD
- Stock Information
- Founded
- NRIX 2009
- TBLD 2021
- Country
- NRIX United States
- TBLD United States
- Employees
- NRIX N/A
- TBLD N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- TBLD Investment Managers
- Sector
- NRIX Health Care
- TBLD Finance
- Exchange
- NRIX Nasdaq
- TBLD Nasdaq
- Market Cap
- NRIX 728.6M
- TBLD 643.6M
- IPO Year
- NRIX 2020
- TBLD N/A
- Fundamental
- Price
- NRIX $8.97
- TBLD $19.89
- Analyst Decision
- NRIX Strong Buy
- TBLD
- Analyst Count
- NRIX 14
- TBLD 0
- Target Price
- NRIX $29.07
- TBLD N/A
- AVG Volume (30 Days)
- NRIX 847.4K
- TBLD 76.8K
- Earning Date
- NRIX 10-10-2025
- TBLD 01-01-0001
- Dividend Yield
- NRIX N/A
- TBLD 6.15%
- EPS Growth
- NRIX N/A
- TBLD N/A
- EPS
- NRIX N/A
- TBLD N/A
- Revenue
- NRIX $88,381,000.00
- TBLD N/A
- Revenue This Year
- NRIX $74.59
- TBLD N/A
- Revenue Next Year
- NRIX N/A
- TBLD N/A
- P/E Ratio
- NRIX N/A
- TBLD N/A
- Revenue Growth
- NRIX 41.86
- TBLD N/A
- 52 Week Low
- NRIX $8.18
- TBLD $15.80
- 52 Week High
- NRIX $29.56
- TBLD $20.55
- Technical
- Relative Strength Index (RSI)
- NRIX 42.73
- TBLD 47.58
- Support Level
- NRIX $8.33
- TBLD $19.86
- Resistance Level
- NRIX $10.13
- TBLD $20.45
- Average True Range (ATR)
- NRIX 0.49
- TBLD 0.31
- MACD
- NRIX -0.00
- TBLD -0.01
- Stochastic Oscillator
- NRIX 35.56
- TBLD 31.71
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About TBLD Thornburg Income Builder Opportunities Trust
Thornburg Income Builder Opportunities Trust is a diversified, closed-end management investment company. The Trust's investment objective is to provide current income. The Trust will seek to achieve its investment objective by investing, directly or indirectly, at least 80% of its Managed Assets.